18F F-AraG-PET Imaging to Evaluate Immunological Response CKI Therapy in Solid Tumors Imaging

• Status: Not yet recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is A pilot study of using [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Fluorides

Criteria

Inclusion Criteria:

• Patients with solid malignancy with planned CkIT treatment as part of their anticancer therapy

• Patient must be ≥ 18 years old

• Documented written informed consent

• A review of prior imaging studies of the patient (CT, MR, or other applicable imaging modality obtained within 28 days prior to CkIT treatment. The patient must have two (2) eligible lesions for AraG PET imaging and biopsy: each lesion must be > 1cm diameter in short axis, with IR investigator's approval for biopsy.

Exclusion Criteria:

• Patient is pregnant or breast feeding